Janney Montgomery Scott LLC Purchases New Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Janney Montgomery Scott LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 3,827 shares of the company's stock, valued at approximately $239,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Quarry LP lifted its holdings in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company's stock worth $58,000 after buying an additional 312 shares during the last quarter. National Bank of Canada FI lifted its holdings in shares of TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company's stock worth $65,000 after buying an additional 262 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock worth $76,000 after buying an additional 316 shares during the last quarter. Rakuten Securities Inc. acquired a new position in shares of TransMedics Group during the third quarter worth approximately $126,000. Finally, Venturi Wealth Management LLC lifted its holdings in shares of TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company's stock worth $136,000 after buying an additional 219 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Remove Ads

TransMedics Group Price Performance

TransMedics Group stock traded up $0.96 during mid-day trading on Friday, hitting $72.18. 1,013,799 shares of the company were exchanged, compared to its average volume of 2,287,730. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The business has a fifty day moving average of $65.87 and a 200 day moving average of $106.53. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a market capitalization of $2.42 billion, a PE ratio of 76.79 and a beta of 2.12.

Analysts Set New Price Targets

TMDX has been the subject of a number of research analyst reports. Canaccord Genuity Group cut their price target on TransMedics Group from $109.00 to $104.00 and set a "buy" rating for the company in a report on Wednesday, November 20th. Oppenheimer restated an "outperform" rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. TD Cowen cut their target price on TransMedics Group from $175.00 to $120.00 and set a "buy" rating for the company in a research note on Monday, November 18th. Piper Sandler cut their target price on TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a research note on Wednesday, December 11th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $122.70.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.